IRF1 and cervical carcinoma: PI3KCA-E545K mutation enhances PD-L1 expression by upregulating PD-L1 transcription factor interferon regulatory factor 1 and that the PIK3CA mutation could be a biomarker for PD-1 blockade treatment in cervical cancer.